Riluzole Dose Escalation in ALS: A Question the Original Trial Already Answered
A single patient, six months into visible functional decline on standard-dose riluzole, asking for more of it. The disagreement turns on whether that request is actually untested territory.
T.K. coached high school football for over two decades before ALS made the job impossible eighteen months ago — the diagnosis came after players started asking why coach's whistle calls sounded thinner by the fourth quarter, a detail T.K. had chalked up to a long season. He started riluzole immediately at the standard dose, 50 milligrams twice daily, and for the first year his ALSFRS-R held reasonably steady, well enough that he still helped run summer conditioning drills from a folding chair on the sideline. Over the past six months it has fallen from 38 to 29, a decline his wife tracks alongside the score sheets she still keeps out of habit, and T.K. has started asking, directly and more than once, whether "more of the drug that's supposed to be helping" might slow things back down. His liver enzymes have run mildly elevated on routine monitoring throughout treatment, stable but never quite normal — a detail nobody has yet connected, in conversation with him, to the dose-increase question he keeps raising.
The honest answer sits in riluzole's own original trial data, not in general dose-response logic. The drug's mechanism — reducing presynaptic glutamate release by blocking voltage-gated sodium channels — targets the excitotoxicity thought to accelerate motor neuron death in ALS, and more of that mechanism might plausibly seem like more protection. But Lacomblez and colleagues' 1996 trial tested three doses head to head — 50, 100, and 200 milligrams per day — and only the 100 mg/day arm, the dose T.K. already takes, showed a significant survival benefit. The 200 mg/day arm, doubling his current dose, showed no additional benefit over 100 mg/day and a higher rate of adverse events, including the same transaminase elevation already visible on his own labs. The trial that established riluzole's benefit is also the trial that already tested and answered the specific escalation T.K. is asking for — three decades ago, before his diagnosis existed to ask the question again.
A request the original trial already tested
His ALSFRS-R has dropped nine points in six months, and he's asking us to do something about it. I understand the pharmacology isn't on our side here, but there's real value in not telling a patient and his family "nothing more can be done" when a dose increase, even one without strong evidence behind it, is technically available and low-risk in the short term.
This isn't actually an absence-of-evidence situation, which is what makes it different from a lot of dose-escalation requests. Lacomblez's own 1996 trial tested exactly this question — 50, 100, and 200 milligrams per day, head to head — and the 200 mg/day arm, double what T.K. takes now, showed no additional survival benefit over 100 mg/day and more adverse events, hepatotoxicity specifically. His own liver enzymes are already mildly elevated. Doubling the dose is asking him to accept more risk for a benefit the original trial already ruled out.
Framing this as "we're not sure, so let's try more" undersells what Lacomblez actually showed — this isn't an untested extrapolation, it's a specific negative result from the same trial that established the standard dose works. Treating it as an open question repeats a comparison that's already been run.
I think the real problem isn't the dose, it's what T.K. and his family are reading into his declining ALSFRS-R. Riluzole's own pivotal trials measured survival and time to needing a tracheostomy or ventilator — not functional scale scores. A falling ALSFRS-R on stable, appropriate dosing isn't evidence the drug has stopped working in the sense it was ever shown to work; it's the expected course of the disease it was never claimed to halt.
I'd hold the dose exactly where it is and have that conversation directly — and then turn the actual clinical energy toward what's driving his six-month decline: his emerging bulbar symptoms and voice fatigue, which have real symptom-directed options that don't carry the toxicity risk this conversation was about to add.
Resolved: riluzole held at 50 mg twice daily. T.K. and his family accepted the explanation once the ALSFRS-R/survival-endpoint distinction was laid out directly, and a speech-language pathology referral was placed for his emerging bulbar symptoms.